NYSE - Delayed Quote • USD
AbbVie Inc. (ABBV)
At close: May 14 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 16 | 16 | 17 | 17 |
| Avg. Estimate | 3.06 | 2.9 | 11.26 | 12.07 |
| Low Estimate | 2.99 | 2.82 | 11.02 | 11.46 |
| High Estimate | 3.11 | 2.94 | 11.4 | 12.71 |
| Year Ago EPS | 2.91 | 2.95 | 11.11 | 11.26 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 15 | 14 | 17 | 17 |
| Avg. Estimate | 14.01B | 14.17B | 55.24B | 58.55B |
| Low Estimate | 13.82B | 13.98B | 54.9B | 57B |
| High Estimate | 14.2B | 14.37B | 55.84B | 60.81B |
| Year Ago Sales | 13.87B | 13.71B | 54.32B | 55.24B |
| Sales Growth (year/est) | 1.10% | 3.40% | 1.70% | 6.00% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 2.81 | 2.86 | 2.77 | 2.23 |
| EPS Actual | 2.91 | 2.95 | 2.79 | 2.31 |
| Difference | 0.1 | 0.09 | 0.02 | 0.08 |
| Surprise % | 3.60% | 3.10% | 0.70% | 3.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 3.06 | 2.9 | 11.26 | 12.07 |
| 7 Days Ago | 3.06 | 2.9 | 11.26 | 12.03 |
| 30 Days Ago | 2.81 | 2.92 | 11.2 | 12.19 |
| 60 Days Ago | 2.81 | 2.92 | 11.19 | 12.2 |
| 90 Days Ago | 2.8 | 2.91 | 11.18 | 12.17 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 15 | 3 | 16 | 8 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | ABBV | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 5.20% | -- | -- | 7.30% |
| Next Qtr. | -1.70% | -- | -- | 10.90% |
| Current Year | 1.40% | -- | -- | 4.60% |
| Next Year | 7.20% | -- | -- | 13.00% |
| Next 5 Years (per annum) | 6.09% | -- | -- | 10.89% |
| Past 5 Years (per annum) | 5.57% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Barclays: Overweight to Overweight | 4/29/2024 |
| Maintains | BMO Capital: Outperform to Outperform | 4/29/2024 |
| Maintains | Barclays: Overweight to Overweight | 3/27/2024 |
| Maintains | Guggenheim: Buy to Buy | 3/22/2024 |
| Maintains | Truist Securities: Buy to Buy | 2/6/2024 |
| Maintains | Raymond James: Outperform | 2/6/2024 |
Related Tickers
JNJ Johnson & Johnson
151.38
+0.11%
MRK Merck & Co., Inc.
128.66
-0.49%
AMGN Amgen Inc.
311.41
+0.96%
BMY Bristol-Myers Squibb Company
44.71
-0.78%
PFE Pfizer Inc.
28.38
-0.21%
LLY Eli Lilly and Company
763.98
+0.83%
GILD Gilead Sciences, Inc.
67.65
+0.16%
AZN AstraZeneca PLC
77.04
-0.50%
GSK GSK plc
45.66
+1.08%
SNY Sanofi
49.50
-1.41%